According to the World Health Organization (WHO), there are more than 70 potential vaccines under development, with three already in clinical trials.
As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.
Signals Analytics’ online COVID-19 Playbook is an analytics platform that uses external data that uncover trends and predictive insights.
Pfizer and BioNTech updated their development program for a COVID-19 vaccine, with plans to launch clinical trials in the U.S. and Europe across multiple sites by the end of April 2020. Pfizer has also chosen a lead antiviral to test against the disease.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
Following close on the heels of the company’s vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19.
Johnson & Johnson is moving forward with a vaccine candidate for COVID-19, with human testing starting during September and the first batches available under potential emergency use authorization expected in the first part of 2021.
As the number of diagnosed cases of COVID-19 continues to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization.
U.S. drugmaker Pfizer Inc. signed a deal with Germany’s BioNTech SE to co-develop a potential vaccine for the coronavirus using BioNTech’s mRNA-based drug development platform, the companies said on Tuesday.
